Brokerages forecast that Heska Corp (NASDAQ:HSKA) will post $0.60 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heska’s earnings, with the highest EPS estimate coming in at $0.60 and the lowest estimate coming in at $0.59. Heska reported earnings of $0.46 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 30.4%. The business is expected to report its next quarterly earnings report on Tuesday, February 27th.
On average, analysts expect that Heska will report full year earnings of $2.03 per share for the current fiscal year, with EPS estimates ranging from $2.00 to $2.04. For the next year, analysts anticipate that the firm will post earnings of $2.05 per share, with EPS estimates ranging from $1.90 to $2.25. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Heska.
HSKA has been the subject of a number of research reports. Sidoti raised Heska from a “neutral” rating to a “buy” rating and set a $94.00 target price for the company in a report on Monday. Aegis reissued a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial reissued a “buy” rating on shares of Heska in a report on Monday, December 4th. BidaskClub raised Heska from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, B. Riley reaffirmed a “hold” rating and issued a $96.50 price target on shares of Heska in a research note on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $110.08.
In related news, insider Michael J. Mcginley sold 7,826 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the transaction, the insider now owns 106,771 shares of the company’s stock, valued at $9,304,024.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 14.70% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of HSKA. Atlantic Trust Group LLC acquired a new position in Heska in the third quarter valued at about $16,059,000. Neuberger Berman Group LLC raised its stake in Heska by 34.2% during the third quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock worth $53,160,000 after acquiring an additional 153,895 shares in the last quarter. Vanguard Group Inc. raised its stake in Heska by 31.7% during the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock worth $47,141,000 after acquiring an additional 111,232 shares in the last quarter. Tygh Capital Management Inc. acquired a new position in Heska during the fourth quarter worth about $5,467,000. Finally, Dimensional Fund Advisors LP raised its stake in Heska by 115.5% during the second quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock worth $12,266,000 after acquiring an additional 64,418 shares in the last quarter. 80.13% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/09/heska-corp-hska-expected-to-post-earnings-of-0-60-per-share.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.